These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37934801)

  • 1. snRNA-seq analysis in multinucleated myogenic FSHD cells identifies heterogeneous FSHD transcriptome signatures associated with embryonic-like program activation and oxidative stress-induced apoptosis.
    Zheng D; Wondergem A; Kloet S; Willemsen I; Balog J; Tapscott SJ; Mahfouz A; van den Heuvel A; van der Maarel SM
    Hum Mol Genet; 2024 Jan; 33(3):284-298. PubMed ID: 37934801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell spatial transcriptomics reveals a dystrophic trajectory following a developmental bifurcation of myoblast cell fates in facioscapulohumeral muscular dystrophy.
    Chen L; Kong X; Johnston KG; Mortazavi A; Holmes TC; Tan Z; Yokomori K; Xu X
    Genome Res; 2024 Jun; 34(5):665-679. PubMed ID: 38777608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development.
    van den Heuvel A; Mahfouz A; Kloet SL; Balog J; van Engelen BGM; Tawil R; Tapscott SJ; van der Maarel SM
    Hum Mol Genet; 2019 Apr; 28(7):1064-1075. PubMed ID: 30445587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-nucleus RNA-seq identifies divergent populations of FSHD2 myotube nuclei.
    Jiang S; Williams K; Kong X; Zeng W; Nguyen NV; Ma X; Tawil R; Yokomori K; Mortazavi A
    PLoS Genet; 2020 May; 16(5):e1008754. PubMed ID: 32365093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression patterns of FSHD-causing DUX4 and myogenic transcription factors PAX3 and PAX7 are spatially distinct in differentiating human stem cell cultures.
    Haynes P; Kernan K; Zhou SL; Miller DG
    Skelet Muscle; 2017 Jun; 7(1):13. PubMed ID: 28637492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation.
    Banerji CRS; Panamarova M; Zammit PS
    Hum Mol Genet; 2020 Aug; 29(14):2285-2299. PubMed ID: 32242220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients.
    Dmitriev P; Bou Saada Y; Dib C; Ansseau E; Barat A; Hamade A; Dessen P; Robert T; Lazar V; Louzada RAN; Dupuy C; Zakharova V; Carnac G; Lipinski M; Vassetzky YS
    Free Radic Biol Med; 2016 Oct; 99():244-258. PubMed ID: 27519269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Facioscapulohumeral dystrophy transcriptome signatures correlate with different stages of disease and are marked by different MRI biomarkers.
    van den Heuvel A; Lassche S; Mul K; Greco A; San León Granado D; Heerschap A; Küsters B; Tapscott SJ; Voermans NC; van Engelen BGM; van der Maarel SM
    Sci Rep; 2022 Jan; 12(1):1426. PubMed ID: 35082321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p38
    Rojas LA; Valentine E; Accorsi A; Maglio J; Shen N; Robertson A; Kazmirski S; Rahl P; Tawil R; Cadavid D; Thompson LA; Ronco L; Chang AN; Cacace AM; Wallace O
    J Pharmacol Exp Ther; 2020 Sep; 374(3):489-498. PubMed ID: 32576599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of the double homeodomain protein DUX4c interferes with myofibrillogenesis and induces clustering of myonuclei.
    Vanderplanck C; Tassin A; Ansseau E; Charron S; Wauters A; Lancelot C; Vancutsem K; Laoudj-Chenivesse D; Belayew A; Coppée F
    Skelet Muscle; 2018 Jan; 8(1):2. PubMed ID: 29329560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interplay between mitochondrial reactive oxygen species, oxidative stress and hypoxic adaptation in facioscapulohumeral muscular dystrophy: Metabolic stress as potential therapeutic target.
    Heher P; Ganassi M; Weidinger A; Engquist EN; Pruller J; Nguyen TH; Tassin A; Declèves AE; Mamchaoui K; Banerji CRS; Grillari J; Kozlov AV; Zammit PS
    Redox Biol; 2022 May; 51():102251. PubMed ID: 35248827
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics.
    Chen JC; King OD; Zhang Y; Clayton NP; Spencer C; Wentworth BM; Emerson CP; Wagner KR
    Mol Ther; 2016 Aug; 24(8):1405-11. PubMed ID: 27378237
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MATR3 is an endogenous inhibitor of DUX4 in FSHD muscular dystrophy.
    Runfola V; Giambruno R; Caronni C; Pannese M; Andolfo A; Gabellini D
    Cell Rep; 2023 Sep; 42(9):113120. PubMed ID: 37703175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells.
    Jagannathan S; Shadle SC; Resnick R; Snider L; Tawil RN; van der Maarel SM; Bradley RK; Tapscott SJ
    Hum Mol Genet; 2016 Oct; 25(20):4419-4431. PubMed ID: 28171552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level.
    Banerji CRS; Zammit PS
    Hum Mol Genet; 2019 Jul; 28(13):2224-2236. PubMed ID: 31067297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Facioscapulohumeral muscular dystrophy family studies of DUX4 expression: evidence for disease modifiers and a quantitative model of pathogenesis.
    Jones TI; Chen JC; Rahimov F; Homma S; Arashiro P; Beermann ML; King OD; Miller JB; Kunkel LM; Emerson CP; Wagner KR; Jones PL
    Hum Mol Genet; 2012 Oct; 21(20):4419-30. PubMed ID: 22798623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Temporal variation in p38-mediated regulation of DUX4 in facioscapulohumeral muscular dystrophy.
    Vangipurapu R; Oliva J; Fox A; Sverdrup FM
    Sci Rep; 2024 Nov; 14(1):26437. PubMed ID: 39488616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic mice expressing tunable levels of DUX4 develop characteristic facioscapulohumeral muscular dystrophy-like pathophysiology ranging in severity.
    Jones TI; Chew GL; Barraza-Flores P; Schreier S; Ramirez M; Wuebbles RD; Burkin DJ; Bradley RK; Jones PL
    Skelet Muscle; 2020 Apr; 10(1):8. PubMed ID: 32278354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolution of DUX4 gene regulation and its implication for facioscapulohumeral muscular dystrophy.
    Jagannathan S
    Biochim Biophys Acta Mol Basis Dis; 2022 May; 1868(5):166367. PubMed ID: 35158020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DUX4 expression in FSHD muscle cells: how could such a rare protein cause a myopathy?
    Tassin A; Laoudj-Chenivesse D; Vanderplanck C; Barro M; Charron S; Ansseau E; Chen YW; Mercier J; Coppée F; Belayew A
    J Cell Mol Med; 2013 Jan; 17(1):76-89. PubMed ID: 23206257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.